Announcements Trials
Browse Landscape

Phase

Phase 2 203Phase 1 92Phase 3 39Phase 1/2 37Phase EARLY_PHASE1 9Phase 4 6Phase NA 3Phase 2/3 3

Status

Completed 2Active not recruiting 2Unknown 1Recruiting 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 6

Sponsor

Cancer Type

Gynecologic 4Genitourinary 2Breast 2Tumor-Agnostic 1Head & Neck 1

Conditions

Ovarian Neoplasms 2Breast Neoplasms 2Thyroid Neoplasms 1Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1BRCA or HRR+ Mutated Ovarian Cancer Patients 1

Interventions

Dexamethasone 56Metformin 50Cyclophosphamide 47Saline Solution 39Cytarabine 37Cisplatin 36Zoledronic Acid 34Letrozole 34Carboplatin 33Sodium Chloride 32Bupivacaine 31Docetaxel 30Bevacizumab 30Vincristine 29Methotrexate 29Fluorouracil 28Propofol 27Capecitabine 27Fentanyl 26Doxorubicin 26Rituximab 25Drug Therapy 25Dexmedetomidine 25Prednisone 23Paclitaxel 23Oxaliplatin 21Morphine 21Gemcitabine 21Radiotherapy 19Prednisolone 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 4 × olaparib × Clear all
NCT05457257 2026-04-21

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

AstraZeneca

Phase 4 Active not recruiting
43 enrolled 16 charts
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT06121401 2025-09-17

IOLANTHE

Mario Negri Institute for Pharmacological Research

Phase 4 Active not recruiting
190 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

NCT04330040 2025-03-10

SOLI

AstraZeneca

Phase 4 Completed
202 enrolled 15 charts
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT05078671 2024-06-12

PROACTIVE

Radboud University Medical Center

Phase 4 Recruiting
160 enrolled
Tumor-Agnostic

Neoplasms

NCT05949424 2023-11-29

OPTI-DOSE

University Medical Center Groningen

Phase 4 Unknown
30 enrolled
BreastGenitourinaryGynecologicHead & Neck

Breast Neoplasms, Carcinoma, Renal Cell, Ovarian Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms

NCT02476968 2022-09-10

ORZORA

AstraZeneca

Phase 4 Completed
181 enrolled 24 charts
Gynecologic

BRCA or HRR+ Mutated Ovarian Cancer Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡